Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Saniona ABCHIX:SANIOS 66 EV-to-EBIT is 5.84 as of Jul. 31, 2026. GuruFocus rates CHIX:SANIOS with a GF Score™ of 66/100 and a GF Value™ of kr26.38 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 384 Biotechnology companies, Saniona AB ranks better than 61.98% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Saniona AB's Enterprise Value for the quarter that ended in Mar. 2026 was kr1,618.5 Mil.
Saniona AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr239.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Saniona AB EV-to-EBIT Related Terms
Saniona AB EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Saniona AB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:SANIOS vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, Saniona AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Saniona AB EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Saniona AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Saniona AB's EV-to-EBIT falls into.
Saniona AB's current Enterprise Value is kr1,397.7 Mil.
Saniona AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr239.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Saniona AB (CHIX:SANIOS) has a EV-to-EBIT of 5.84 as of Jul. 31, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Saniona AB and its competitors. According to the industry distribution chart, Saniona AB ranks #146 out of 384 companies in the Biotechnology industry, placing it in the top 38%.
Is Saniona AB's EV-to-EBIT too high?
Saniona AB's current EV-to-EBIT is 5.84. The Biotechnology industry median EV-to-EBIT is 12.17. Saniona AB's value of 5.84 is 52% below this industry median. Based on the distribution chart, Saniona AB ranks #146 out of 384 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Saniona AB has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Saniona AB's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Saniona AB ranks #146 out of 384 companies for EV-to-EBIT. This puts Saniona AB in the upper half of its industry. The industry median EV-to-EBIT is 12.17. Saniona AB's value of 5.84 is 52% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.17, based on 384 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Saniona AB's current EV-to-EBIT of 5.84 is 52% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Saniona AB and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Saniona AB's current EV-to-EBIT is 5.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Saniona AB stock overvalued right now?
Based on GuruFocus' analysis, Saniona AB (CHIX:SANIOS) is currently considered Significantly Undervalued. The stock's GF Value™ is kr26.38, compared to a current price of kr12.94 — trading 50.9% below its estimated fair value. The current EV-to-EBIT is 5.84 and 52% below the Biotechnology industry median of 12.17. Saniona AB's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Saniona AB (CHIX:SANIOS), the current EV-to-EBIT is 5.84 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Saniona AB (CHIX:SANIOS) Overvalued in 2026?
Based on GuruFocus' analysis, Saniona AB stock appears to be undervalued.
The current stock price of kr12.94 is trading 50.9% below its estimated GF Value™ of kr26.38.
GuruFocus considers Saniona AB to be Significantly Undervalued.
Key valuation signals for CHIX:SANIOS:
EV-to-EBIT: 5.84
GF Value™: kr26.38 vs. price of kr12.94 (50.9% below fair value)
Industry Position: 52% below the Biotechnology median (#146 of 384)
No single metric tells the full story. See the CHIX:SANIOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Saniona AB researches and develops drugs for the treatment of diseases of the central nervous system, autoimmune diseases, metabolic diseases, and the treatment of pain. It develops a technology platform that enables the investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors, and potassium channels. The company product pipeline includes Tesomet, SAN711, Tesofensine, SAN903, and SAN2219. Geographically, it operates in USA, Sweden, Germany, Denmark, and United Kingdom, out of which it derives maximum revenue from USA.
66GF Score
Get the complete analysis for CHIX:SANIOS
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:SANIOS has been successfully added to your 
